rs7850258 — PTCSC2

Intronic variant in the PTCSC2 lncRNA that alters a FOXE1 enhancer element, modulating thyroid gland development and hypothyroidism risk

See your personal result for PTCSC2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

The FOXE1 Enhancer Switch That Sets Your Thyroid's Developmental Tone

About 67.7 kilobases upstream of the FOXE1 gene — a master regulator of thyroid gland formation — sits a conserved enhancer element that fine-tunes how much FOXE1 protein the developing and adult thyroid produces. The rs7850258 variant sits inside this enhancer and changes which transcription factors can bind there. The result is a meaningful shift in thyroid development trajectory and lifetime hypothyroidism risk, embedded in the 9q22.33 thyroid disease locus11 the 9q22.33 thyroid disease locus
One of the most replicated genetic regions in thyroid medicine, containing multiple independent signals for thyroid cancer, hypothyroidism, and TSH levels.

The Mechanism

FOXE122 FOXE1
Forkhead Box E1, also known as thyroid transcription factor 2 (TTF-2) is essential for thyroid morphogenesis — mice lacking FOXE1 fail to form a thyroid gland. In adults, FOXE1 maintains the differentiated state of thyroid follicular cells. The rs7850258 variant determines whether a specific E-box sequence in the upstream enhancer is active or dormant.

The G allele creates a functional E-box motif that recruits MYC and ARNT transcription factors33 MYC and ARNT transcription factors
Two bHLH proteins that bind E-box (CACGTG) sequences; their binding is 1.2–1.7-fold stronger at the G allele than the A allele in luciferase reporter assays. This stronger binding drives greater enhancer activity, pushing FOXE1 expression higher during thyroid development. Counter-intuitively, higher embryonic FOXE1 expression appears to disrupt normal thyroid morphogenesis rather than enhance it — possibly by inducing apoptosis or altering the timing of follicular cell differentiation — resulting in a thyroid gland with subtly reduced functional reserve in G-allele carriers. The A allele, by contrast, lacks strong E-box binding and is associated with reduced FOXE1 enhancer output, which (by a separate mechanism) creates a permissive environment for thyroid tumour development.

This creates the unusual situation where the G allele raises hypothyroidism risk while the A allele raises thyroid cancer risk — the same locus pushes the thyroid toward different pathological endpoints depending on the direction of FOXE1 dysregulation.

The Evidence

The discovery study by Denny et al. 201144 Denny et al. 2011
American Journal of Human Genetics, 1,317 hypothyroidism cases + 5,053 controls, replication in 263 + 1,616 controls identified rs7850258 as the strongest GWAS signal for hypothyroidism at the 9q22 locus (OR 1.35 per G allele, p = 3.96 × 10⁻⁹ under an additive model). The same variant also reached significance for thyroiditis (OR per G ~1.72), nodular goiter, and thyrotoxicosis, establishing it as a broad thyroid-function modulator. The A allele was present at 34.8% in controls versus only 28.5% in hypothyroidism cases, confirming the protective direction.

The functional mechanism was established by Lidral et al. 201555 Lidral et al. 2015
Human Molecular Genetics, multi-tissue enhancer assays in oral epithelial and thyroid cell lines. The G allele showed 1.2- to 1.7-fold greater enhancer activity across multiple cell types compared to the A allele. Transcription factor binding assays confirmed the G allele E-box recruits MYC and ARNT — proteins absent from the A-allele binding profile — providing a mechanistic explanation for the epidemiological associations.

Large-scale replication came from Mathieu et al. 202266 Mathieu et al. 2022
iScience, 51,194 hypothyroidism cases and 443,383 controls, which identified 139 hypothyroidism risk loci and confirmed rs7850258 as a genome-wide significant signal (beta = −0.212 per protective A allele). The Verma et al. 2024 multi-ancestry GWAS77 Verma et al. 2024 multi-ancestry GWAS
Science, ~636,000 participants across ancestries further confirmed the association with thyroid medication use (a proxy for hypothyroidism requiring treatment) at p = 2 × 10⁻¹¹⁹ — one of the most replicated endocrine GWAS signals outside of the major histocompatibility complex.

Practical Actions

For GG carriers (~52% of the population), the approximately 80% increased hypothyroidism risk compared to AA carriers justifies proactive TSH monitoring starting earlier than standard population guidelines. Current screening guidelines in many countries suggest TSH testing beginning at age 35–40; GG carriers have grounds to begin at 25–30 and repeat every 3–5 years. When TSH is borderline-high but still within the laboratory reference range (the so-called "high-normal" TSH between 2.5–4.5 mIU/L), additional context from a geneticist or endocrinologist is warranted before dismissing it as normal.

For individuals already diagnosed with hypothyroidism or subclinical hypothyroidism, this genotype helps explain the underlying susceptibility and does not change standard treatment decisions. However, when combined with the DIO2 Thr92Ala variant (rs225014), the combination of impaired thyroid functional reserve (this SNP) and impaired T4-to-T3 conversion (DIO2) may produce more pronounced symptoms at borderline thyroid function levels — a context where early treatment initiation may be warranted.

Interactions

rs7850258 lies approximately 7 kb from rs965513 — the strongest papillary thyroid cancer GWAS locus at 9q22.33. These two variants are in or near the same LD block and may represent partially overlapping genetic signals at the PTCSC2/ FOXE1 regulatory region. The allele directions are complementary: G at rs7850258 (hypothyroidism risk) tends to co-occur with the G allele at rs965513 (which is protective for thyroid cancer), creating an inverse relationship between hypothyroidism and thyroid cancer risk at this locus.

The variant also sits within the same functional genomic region studied for rs1867277 (FOXE1 5' UTR) and rs944289 (14q13.3), which are independent thyroid cancer risk loci. These variants operate through distinct regulatory mechanisms but all converge on FOXE1 expression regulation.

Compound implication for rs7850258-GG + DIO2 rs225014-CC: Individuals carrying both the hypothyroidism-risk GG genotype at rs7850258 and two copies of the DIO2 Thr92Ala variant may experience compound thyroid function challenges — reduced thyroid gland functional reserve combined with impaired peripheral T4-to-T3 conversion. If you have this combination and are on levothyroxine, discuss free T3 monitoring and possible combination T4/T3 therapy with your endocrinologist.

Genotype Interpretations

What each possible genotype means for this variant.

AA Protective Genotype Beneficial

Reduced hypothyroidism risk — A-allele homozygote

The A allele at rs7850258 fails to recruit MYC and ARNT transcription factors to the E-box enhancer motif, resulting in lower FOXE1 enhancer activity (1.2–1.7-fold less than the G allele). This lower developmental FOXE1 output appears to be associated with normal thyroid morphogenesis and functional reserve in the vast majority of AA carriers. The Denny 2011 study found the A allele frequency was 34.8% in controls vs 28.5% in hypothyroidism cases, and under the additive model, each A allele reduces hypothyroidism odds by approximately 26%. For AA homozygotes, this translates to approximately 44% lower odds than the average population.

Note that this same A allele has been associated with a modestly elevated papillary thyroid cancer risk (via the Lidral 2015 functional study), though this cancer association is driven by a distinct mechanism from the hypothyroidism pathway. Standard thyroid cancer screening is appropriate.

AG Intermediate Risk Intermediate

One copy of the hypothyroidism-risk G allele — modestly elevated risk

Under the additive model established in Denny 2011, the AG genotype confers approximately 35% greater hypothyroidism odds than the AA genotype (one copy of the OR ~1.35 effect). This is a modest population-level effect that represents a shift in baseline risk, not a diagnostic indicator. The large hypothyroidism GWAS by Mathieu et al. 2022 (51,194 cases) confirmed this locus at genome-wide significance, underscoring its robustness across diverse populations.

Your thyroid function is likely to remain normal throughout life, but being aware of early hypothyroid symptoms — fatigue, cold intolerance, weight gain, constipation, slowed cognition — and ensuring periodic TSH monitoring is prudent, particularly if you also carry other thyroid-related variants such as DIO2 rs225014 (impaired T4-to-T3 conversion) or additional 9q22 locus variants.

GG Elevated Risk High Risk

Two copies of the hypothyroidism-risk G allele — substantially elevated thyroid function risk

The GG genotype frequency is highest in East Asian populations (~77% GG) and lower in Europeans (~44% GG). The Denny 2011 PheWAS analysis found that beyond hypothyroidism, the G allele also associated with thyroiditis, nodular goiter, and thyrotoxicosis — suggesting that this variant broadly affects thyroid gland stability rather than specifically predisposing to a single condition.

Importantly, the G allele at rs7850258 appears inversely correlated with the risk conferred by the nearby rs965513 A allele (thyroid cancer risk): haplotypes carrying G at rs7850258 tend to carry G at rs965513, which is the protective (non-cancer-risk) allele. This means GG carriers at rs7850258 likely face elevated hypothyroidism risk but not elevated thyroid cancer risk from this genomic region — though this should be confirmed with rs965513 genotyping.

The Lidral 2015 mechanistic study showed the G allele enhancer is 1.2–1.7-fold more active in thyroid cell lines, with the excess FOXE1 activation potentially inducing apoptosis or disrupting the timing of follicular cell differentiation during thyroid organogenesis. The resulting thyroid may have marginally reduced reserve capacity and be more vulnerable to TSH-driven demand (e.g., during pregnancy, iodine insufficiency, or autoimmune insult).